AI governance catching up

Healthcare groups are deploying artificial intelligence faster than regulators are enforcing it, even as drugmakers and universities sign bigger enterprise deals. (healthcareitnews.com) (biospace.com) (polsky.uchicago.edu) On April 14, 2026, Novo Nordisk said it had entered a strategic partnership with OpenAI to use advanced artificial intelligence across global operations, from drug discovery to commercial work. The company said the arrangement includes workforce upskilling, strict data governance, and human oversight. (biospace.com) That same day, the University of Chicago’s Polsky Center and Data Science Institute said they were partnering with AI Research Commons, Microsoft, and NVIDIA to back early-stage artificial intelligence startups from Third Coast Foundry universities. The program is aimed at Midwest companies and ties university research more directly to cloud, chip, and commercialization support. (polsky.uchicago.edu) In healthcare, artificial intelligence often means software that scans images, predicts risk, drafts notes, or helps staff sort large datasets. The compliance problem is that the same tool can touch medical-device rules, patient-privacy law, billing rules, and consumer-protection law at the same time. (fda.gov) (hhs.gov) (ftc.gov) Federal oversight already exists in pieces. The Food and Drug Administration says its artificial-intelligence-enabled medical device list identifies products authorized for marketing in the United States, while the Department of Health and Human Services Office for Civil Rights enforces health-information privacy and security rules. (fda.gov) (hhs.gov) Enforcement is also widening beyond classic healthcare regulators. On September 25, 2024, the Federal Trade Commission announced Operation AI Comply, a law-enforcement sweep targeting deceptive claims and unfair conduct tied to artificial intelligence. (ftc.gov) Outside the United States, the European Union’s Artificial Intelligence Act classifies some systems as high-risk when they are safety components of regulated products or fall into listed use cases. That gives hospitals, device makers, and software vendors another rulebook if they build or sell across borders. (ai-act-service-desk.ec.europa.eu) Law firms and hospital advisers have spent the past year warning that state laws are starting to fill gaps left by slower federal action. Healthcare IT News reported on April 14, 2026 that one attorney expects future cases to focus on governance, documentation, and oversight as artificial intelligence becomes routine in care delivery. (healthcareitnews.com) (mintz.com) (fenwick.com) The result is a split-screen market in April 2026: companies are treating artificial intelligence as core infrastructure, while regulators are still stitching together how to police it. That leaves hospitals, drugmakers, and universities building governance systems at the same time they expand adoption. (biospace.com) (polsky.uchicago.edu) (healthcareitnews.com)